<p>Squarepoint Ops LLC 在最近向证券交易委员会提交的 13F 文件中披露，在第二季度将其在 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - 免费报告) 的持股减少了 56.0%。该机构投资者在季度内出售了 170,978 股后，持有该公司 134,395 股股票。Squarepoint Ops LLC 在最近一个季度末持有的 Ionis Pharmaceuticals 的股份约占 0.08%，价值 5,310,000 美元。</p>
<p>获取 <strong>Ionis Pharmaceuticals</strong> 警报：</p>
<ul>
<li>这 5 只被低估的股票准备突破吗？</li>
</ul>
<p>其他一些对冲基金和机构投资者也买卖了该公司的股票。PNC Financial Services Group Inc. 在第二季度将其在 Ionis Pharmaceuticals 的股份增加了 3.9%。PNC Financial Services Group Inc. 现在持有 11,411 股该公司的股票，价值 451,000 美元，此前在此期间又购买了 424 股。Allworth Financial LP 在第二季度将其在 Ionis Pharmaceuticals 的持股增加了 231.8%。Allworth Financial LP 现在持有 740 股该公司的股票，价值 29,000 美元，此前又收购了 517 股。Signaturefd LLC 在第二季度将其在 Ionis Pharmaceuticals 的股份增加了 46.9%。Signaturefd LLC 现在持有 2,030 股该公司的股票，价值 80,000 美元，此前在上个季度又购买了 648 股。Corient Private Wealth LLC 在第二季度将其在 Ionis Pharmaceuticals 的持股增加了 0.3%。Corient Private Wealth LLC 现在持有 237,931 股该公司的股票，价值 9,401,000 美元，此前在上个季度又购买了 798 股。最后，Mirae Asset Global Investments Co. Ltd. 在第二季度将其在 Ionis Pharmaceuticals 的持股增加了 15.6%。Mirae Asset Global Investments Co. Ltd. 现在持有 6,148 股该公司的股票，价值 243,000 美元，此前又购买了 829 股。机构投资者持有该公司 93.86% 的股份。</p>
<h2>Ionis Pharmaceuticals 的内部买卖</h2>
<p>在 Ionis Pharmaceuticals 的其他消息中，执行副总裁 Patrick R. O'neil 于 10 月 2 日星期四出售了 64,664 股该公司的股票。股票以平均价格 67.69 美元出售，总价值为 4,377,106.16 美元。交易完成后，该执行副总裁直接持有 57,130 股公司股票，价值约 3,867,129.70 美元。这代表了其持股的 53.09% 的减少。该出售在向证券交易委员会提交的文件中披露，可以通过 SEC 网站访问。此外，董事 Joseph H. Wender 于 12 月 1 日星期一出售了 28,000 股 Ionis Pharmaceuticals 股票。股票以平均价格 80.82 美元出售，总交易额为 2,262,960.00 美元。出售后，该董事直接持有 36,035 股公司股票，价值 2,912,348.70 美元。这笔交易是其持股的 43.73% 的减少。该出售的披露在 SEC 文件中可用。在上个季度，内部人士出售了价值 35,744,766 美元的 504,866 股公司股票。2.71% 的股票由公司内部人士持有。</p>
<h2>Ionis Pharmaceuticals 股票上涨 2.1%</h2>
<p>NASDAQ:IONS 的股票在周一开盘时为 80.82 美元。Ionis Pharmaceuticals, Inc. 的 12 个月低点为 23.95 美元，12 个月高点为 83.61 美元。该公司的流动比率为 2.79，速动比率为 2.78，债务与股本比率为 0.96。该股票的 50 天移动平均价格为 74.91 美元，200 天移动平均价格为 56.35 美元。该股票的市值为 130.9 亿美元，市盈率为 -47.82，贝塔系数为 0.29。</p>
<p>Ionis Pharmaceuticals (NASDAQ:IONS - 获取免费报告) 最近于 10 月 29 日星期三发布了季度财报。该公司报告季度每股收益 (EPS) 为 -0.80，超过市场共识预期的 -1.15，超出 0.35。该公司季度收入为 1.5672 亿美元，而分析师预期为 1.3175 亿美元。Ionis Pharmaceuticals 的股本回报率为 -44.26%，净利润率为 -26.45%。Ionis Pharmaceuticals 本季度的收入较去年同期增长了 17.2%。去年同期，该公司每股收益为 -0.95。平均而言，股票分析师预计 Ionis Pharmaceuticals, Inc. 本年度每股收益将为 -3.5。</p>
<h2>分析师设定新目标价</h2>
<p>多位股票分析师对 IONS 股票发表了看法。摩根士丹利将 Ionis Pharmaceuticals 的目标价从 90.00 美元上调至 94.00 美元，并在 10 月 30 日星期四的研究报告中给予该股票 &#34;超配&#34; 评级。TD Cowen 将 Ionis Pharmaceuticals 的目标价从 59.00 美元上调至 99.00 美元，并在 10 月 30 日星期四的研究报告中给予该股票 &#34;买入&#34; 评级。花旗集团将 Ionis Pharmaceuticals 的目标价从 69.00 美元上调至 84.00 美元，并在 9 月 3 日星期三的研究报告中给予该公司 &#34;买入&#34; 评级。BMO Capital Markets 将 Ionis Pharmaceuticals 的评级从 &#34;市场表现&#34; 上调至 &#34;跑赢大盘&#34;，并在 9 月 3 日星期三的研究报告中将该股票的目标价从 40.00 美元上调至 70.00 美元。最后，富国银行将 Ionis Pharmaceuticals 的目标价从 77.00 美元上调至 82.00 美元，并在 8 月 22 日星期五的报告中给予该股票 &#34;超配&#34; 评级。一位研究分析师对该股票给予了强烈买入评级，十七位给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Ionis Pharmaceuticals 的平均评级为 &#34;适度买入&#34;，共识目标价为 84.85 美元。</p>
<p><strong>获取我们关于 IONS 的最新报告</strong></p>
<h2>Ionis Pharmaceuticals 简介</h2>
<p>(免费报告)</p>
<p>Ionis Pharmaceuticals, Inc. 在美国发现和开发针对 RNA 的治疗药物。该公司为儿童和成人患者提供用于脊髓性肌萎缩症（SMA）的 SPINRAZA；TEGSEDI，一种用于治疗由遗传性转甲状腺素淀粉样变引起的多发性神经病的抗病毒注射剂；以及 WAYLIVRA，一种用于治疗家族性乳糜微粒血症（FCS）和家族性部分脂肪营养不良的抗病毒药物。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比 Ionis Pharmaceuticals 更好的股票</li>
<li>什么是股息？购买最佳股息股票</li>
<li>3 只被低估的机器人股票，准备迎来巨额收益</li>
<li>股票回购是什么？投资者的全面指南</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了 PLAY</li>
<li>如何从价值投资中获利</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU9OUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU9OUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Ionis Pharmaceuticals 吗？</h2>
<p>在考虑 Ionis Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Ionis Pharmaceuticals 并不在名单上。</p>
<p>虽然 Ionis Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Ionis制药

<p>Squarepoint Ops LLC 在第二季度减少了对 Ionis Pharmaceuticals 的持股，减持幅度为 56%，出售了 170,978 股。该公司目前持有 134,395 股，价值 531 万美元。其他机构投资者也调整了在 Ionis 的持仓。内部人士在上个季度出售了 504,866 股，价值 3,574 万美元。Ionis 股票上涨了 2.1%，市值为 130.9 亿美元。该公司报告第三季度收入为 1.5672 亿美元，同比增长 17.2%，每股净亏损 0.80 美元，超出预期</p>

<p>Squarepoint Ops LLC reduced its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 56.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 134,395 shares of the company's stock after selling 170,978 shares during the quarter. Squarepoint Ops LLC owned about 0.08% of Ionis Pharmaceuticals worth $5,310,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Squarepoint Ops LLC 在最近向证券交易委员会提交的 13F 文件中披露，在第二季度将其在 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - 免费报告) 的持股减少了 56.0%。该机构投资者在季度内出售了 170,978 股后，持有该公司 134,395 股股票。Squarepoint Ops LLC 在最近一个季度末持有的 Ionis Pharmaceuticals 的股份约占 0.08%，价值 5,310,000 美元。</p>
</div><p>Get <strong>Ionis Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Ionis Pharmaceuticals</strong> 警报：</p>
</div><ul>
<li>Are These 5 Undervalued Stocks Ready to Break Out?</li>
</ul>
<div class="lb-trans"><ul>
<li>这 5 只被低估的股票准备突破吗？</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also bought and sold shares of the business. PNC Financial Services Group Inc. raised its stake in shares of Ionis Pharmaceuticals by 3.9% during the 2nd quarter. PNC Financial Services Group Inc. now owns 11,411 shares of the company's stock valued at $451,000 after purchasing an additional 424 shares during the period. Allworth Financial LP boosted its position in shares of Ionis Pharmaceuticals by 231.8% in the second quarter. Allworth Financial LP now owns 740 shares of the company's stock valued at $29,000 after acquiring an additional 517 shares during the period. Signaturefd LLC lifted its stake in Ionis Pharmaceuticals by 46.9% in the 2nd quarter. Signaturefd LLC now owns 2,030 shares of the company's stock worth $80,000 after purchasing an additional 648 shares in the last quarter. Corient Private Wealth LLC grew its position in shares of Ionis Pharmaceuticals by 0.3% during the 2nd quarter. Corient Private Wealth LLC now owns 237,931 shares of the company's stock valued at $9,401,000 after purchasing an additional 798 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Ionis Pharmaceuticals by 15.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,148 shares of the company's stock worth $243,000 after purchasing an additional 829 shares during the period. Institutional investors own 93.86% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者也买卖了该公司的股票。PNC Financial Services Group Inc. 在第二季度将其在 Ionis Pharmaceuticals 的股份增加了 3.9%。PNC Financial Services Group Inc. 现在持有 11,411 股该公司的股票，价值 451,000 美元，此前在此期间又购买了 424 股。Allworth Financial LP 在第二季度将其在 Ionis Pharmaceuticals 的持股增加了 231.8%。Allworth Financial LP 现在持有 740 股该公司的股票，价值 29,000 美元，此前又收购了 517 股。Signaturefd LLC 在第二季度将其在 Ionis Pharmaceuticals 的股份增加了 46.9%。Signaturefd LLC 现在持有 2,030 股该公司的股票，价值 80,000 美元，此前在上个季度又购买了 648 股。Corient Private Wealth LLC 在第二季度将其在 Ionis Pharmaceuticals 的持股增加了 0.3%。Corient Private Wealth LLC 现在持有 237,931 股该公司的股票，价值 9,401,000 美元，此前在上个季度又购买了 798 股。最后，Mirae Asset Global Investments Co. Ltd. 在第二季度将其在 Ionis Pharmaceuticals 的持股增加了 15.6%。Mirae Asset Global Investments Co. Ltd. 现在持有 6,148 股该公司的股票，价值 243,000 美元，此前又购买了 829 股。机构投资者持有该公司 93.86% 的股份。</p>
</div><h2>Insider Buying and Selling at Ionis Pharmaceuticals</h2>
<div class="lb-trans"><h2>Ionis Pharmaceuticals 的内部买卖</h2>
</div><p>In other Ionis Pharmaceuticals news, EVP Patrick R. O'neil sold 64,664 shares of the company's stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $67.69, for a total value of $4,377,106.16. Following the completion of the transaction, the executive vice president directly owned 57,130 shares in the company, valued at approximately $3,867,129.70. This represents a 53.09% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, Director Joseph H. Wender sold 28,000 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $80.82, for a total transaction of $2,262,960.00. Following the sale, the director directly owned 36,035 shares in the company, valued at $2,912,348.70. The trade was a 43.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 504,866 shares of company stock worth $35,744,766. 2.71% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在 Ionis Pharmaceuticals 的其他消息中，执行副总裁 Patrick R. O'neil 于 10 月 2 日星期四出售了 64,664 股该公司的股票。股票以平均价格 67.69 美元出售，总价值为 4,377,106.16 美元。交易完成后，该执行副总裁直接持有 57,130 股公司股票，价值约 3,867,129.70 美元。这代表了其持股的 53.09% 的减少。该出售在向证券交易委员会提交的文件中披露，可以通过 SEC 网站访问。此外，董事 Joseph H. Wender 于 12 月 1 日星期一出售了 28,000 股 Ionis Pharmaceuticals 股票。股票以平均价格 80.82 美元出售，总交易额为 2,262,960.00 美元。出售后，该董事直接持有 36,035 股公司股票，价值 2,912,348.70 美元。这笔交易是其持股的 43.73% 的减少。该出售的披露在 SEC 文件中可用。在上个季度，内部人士出售了价值 35,744,766 美元的 504,866 股公司股票。2.71% 的股票由公司内部人士持有。</p>
</div><h2>Ionis Pharmaceuticals Stock Up 2.1%</h2>
<div class="lb-trans"><h2>Ionis Pharmaceuticals 股票上涨 2.1%</h2>
</div><p>Shares of NASDAQ:IONS opened at $80.82 on Monday. Ionis Pharmaceuticals, Inc. has a 12-month low of $23.95 and a 12-month high of $83.61. The company has a current ratio of 2.79, a quick ratio of 2.78 and a debt-to-equity ratio of 0.96. The stock's 50-day moving average price is $74.91 and its 200-day moving average price is $56.35. The stock has a market capitalization of $13.09 billion, a P/E ratio of -47.82 and a beta of 0.29.</p>
<div class="lb-trans"><p>NASDAQ:IONS 的股票在周一开盘时为 80.82 美元。Ionis Pharmaceuticals, Inc. 的 12 个月低点为 23.95 美元，12 个月高点为 83.61 美元。该公司的流动比率为 2.79，速动比率为 2.78，债务与股本比率为 0.96。该股票的 50 天移动平均价格为 74.91 美元，200 天移动平均价格为 56.35 美元。该股票的市值为 130.9 亿美元，市盈率为 -47.82，贝塔系数为 0.29。</p>
</div><p>Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last posted its quarterly earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.35. The business had revenue of $156.72 million for the quarter, compared to analyst estimates of $131.75 million. Ionis Pharmaceuticals had a negative return on equity of 44.26% and a negative net margin of 26.45%.Ionis Pharmaceuticals's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period last year, the company earned ($0.95) EPS. On average, equities analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.</p>
<div class="lb-trans"><p>Ionis Pharmaceuticals (NASDAQ:IONS - 获取免费报告) 最近于 10 月 29 日星期三发布了季度财报。该公司报告季度每股收益 (EPS) 为 -0.80，超过市场共识预期的 -1.15，超出 0.35。该公司季度收入为 1.5672 亿美元，而分析师预期为 1.3175 亿美元。Ionis Pharmaceuticals 的股本回报率为 -44.26%，净利润率为 -26.45%。Ionis Pharmaceuticals 本季度的收入较去年同期增长了 17.2%。去年同期，该公司每股收益为 -0.95。平均而言，股票分析师预计 Ionis Pharmaceuticals, Inc. 本年度每股收益将为 -3.5。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of equities analysts have weighed in on IONS shares. Morgan Stanley upped their target price on Ionis Pharmaceuticals from $90.00 to $94.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday, October 30th. TD Cowen upped their price objective on shares of Ionis Pharmaceuticals from $59.00 to $99.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, October 30th. Citigroup raised their target price on shares of Ionis Pharmaceuticals from $69.00 to $84.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, September 3rd. BMO Capital Markets raised shares of Ionis Pharmaceuticals from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and boosted their price target for the stock from $40.00 to $70.00 in a research note on Wednesday, September 3rd. Finally, Wells Fargo &amp; Company lifted their price objective on shares of Ionis Pharmaceuticals from $77.00 to $82.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, August 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Ionis Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $84.85.</p>
<div class="lb-trans"><p>多位股票分析师对 IONS 股票发表了看法。摩根士丹利将 Ionis Pharmaceuticals 的目标价从 90.00 美元上调至 94.00 美元，并在 10 月 30 日星期四的研究报告中给予该股票 &#34;超配&#34; 评级。TD Cowen 将 Ionis Pharmaceuticals 的目标价从 59.00 美元上调至 99.00 美元，并在 10 月 30 日星期四的研究报告中给予该股票 &#34;买入&#34; 评级。花旗集团将 Ionis Pharmaceuticals 的目标价从 69.00 美元上调至 84.00 美元，并在 9 月 3 日星期三的研究报告中给予该公司 &#34;买入&#34; 评级。BMO Capital Markets 将 Ionis Pharmaceuticals 的评级从 &#34;市场表现&#34; 上调至 &#34;跑赢大盘&#34;，并在 9 月 3 日星期三的研究报告中将该股票的目标价从 40.00 美元上调至 70.00 美元。最后，富国银行将 Ionis Pharmaceuticals 的目标价从 77.00 美元上调至 82.00 美元，并在 8 月 22 日星期五的报告中给予该股票 &#34;超配&#34; 评级。一位研究分析师对该股票给予了强烈买入评级，十七位给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Ionis Pharmaceuticals 的平均评级为 &#34;适度买入&#34;，共识目标价为 84.85 美元。</p>
</div><p><strong>Get Our Latest Report on IONS</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 IONS 的最新报告</strong></p>
</div><h2>Ionis Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Ionis Pharmaceuticals 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.</p>
<div class="lb-trans"><p>Ionis Pharmaceuticals, Inc. 在美国发现和开发针对 RNA 的治疗药物。该公司为儿童和成人患者提供用于脊髓性肌萎缩症（SMA）的 SPINRAZA；TEGSEDI，一种用于治疗由遗传性转甲状腺素淀粉样变引起的多发性神经病的抗病毒注射剂；以及 WAYLIVRA，一种用于治疗家族性乳糜微粒血症（FCS）和家族性部分脂肪营养不良的抗病毒药物。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Ionis Pharmaceuticals</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>3 Underrated Robotics Stocks Poised for Huge Gains</li>
<li>What is a buyback in stocks? A comprehensive guide for investors</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>How to Profit From Value Investing</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Ionis Pharmaceuticals 更好的股票</li>
<li>什么是股息？购买最佳股息股票</li>
<li>3 只被低估的机器人股票，准备迎来巨额收益</li>
<li>股票回购是什么？投资者的全面指南</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了 PLAY</li>
<li>如何从价值投资中获利</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU9OUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=IONS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Ionis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Ionis Pharmaceuticals 吗？</h2>
</div><p>Before you consider Ionis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Ionis Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Ionis Pharmaceuticals 并不在名单上。</p>
</div><p>While Ionis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ionis Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Squarepoint Ops LLC 出售了 170,978 股 Ionis 制药公司的股票，股票代码为$IONS